home > ict > summer 2021 > future factories – optimising operations
International Clinical Trials

Future Factories – Optimising Operations

At the height of the pandemic crisis, the pharma industry faced urgent pressure to accelerate its operations. The planet’s health – quite literally – depended on it. Amid the unprecedented global need for large quantities of inoculations, it became increasingly critical for vaccine producers to take advantage of the recent advances in process digitisation. The world has since benefitted from the remarkably swift development of life-saving COVID-19 vaccines.

Process development (PD) in the pharma industry now involves more data-driven decision-making and risk assessment than ever before. Under new PD models, companies leverage more data, automation, and modelling to reduce risks and establish a holistic, transferable control strategy.

Industry time-to-market is shorter than ever, and development cycle times are shrinking. These process improvements make the industry better able to rise to the challenge of meeting global health needs as they occur, meaning a safer, healthier future for all.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
About the Author

Perry Zalevsky is the Senior Director of the Industry team at AVEVA, which includes the pharmaceutical and life science industries. With over 30 years of experience working with a variety of companies, on process and product improvement projects, Perry has developed a number of mathematical and AI-based models to help with business and manufacturing/ operational enhancements. He has previously worked at SAP as an Industry Principal, and prior to that at other supply chain software companies. Perry holds a BSc in Applied Mathematics and an MSc degree in Operations Research, both from Carnegie Mellon University in Pittsburgh, Pennsylvania, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avantor to Acquire Masterflex; Expands Proprietary Single-Use Offering for Bioproduction

RADNOR, Pa., Sept. 7, 2021 /PRNewswire/ – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, today announced that it has entered into a definitive agreement to acquire the Masterflex bioprocessing business and related assets (collectively "Masterflex") of Antylia Scientific.
More info >>

White Papers

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

Temptime Corporation

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement